Disseminated superficial actinic porokeratosis (DSAP) is a disorder of abnormal keratinization for which there is no standard treatment. Treatment modalities that have traditionally been utilized with varying success include ablative therapies, topical pharmacologic treatments, surgical excision, and retinoids. The underlying pathophysiology of DSAP is secondary to genetic mutations in the mevalonate biosynthesis pathway, and thus topical lovastatin/cholesterol presents a promising treatment modality for this condition. We present a case of familial DSAP successfully treated with topical lovastatin/cholesterol gel and provide a brief review of the existing literature surrounding this novel therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352470 | PMC |
| http://dx.doi.org/10.7759/cureus.40582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malignant Transformation in Porokeratosis Ptychotropica: A Systematic Review.
Acta Derm Venereol
October 2024
Department of Dermatology, National University Hospital, Singapore; Department of Medicine, National University of Singapore, Singapore.
Porokeratosis ptychotropica (PP) is a rare and unusual variant of porokeratosis. There is a dearth of information on the natural history, epidemiology, and optimal treatment options. This study aimed to characterize the worldwide distribution, epidemiology, clinical features, and treatments attempted for all reported cases of porokeratosis ptychotropica.
View Article and Find Full Text PDFPorokeratosis of Mibelli Treated With Topical 2% Lovastatin/2% Cholesterol Ointment.
Cureus
July 2024
Department of Dermatology, Poznan University of Medical Sciences, Poznan, POL.
Article Synopsis
- Porokeratosis is a skin condition caused by disruptions in the isoprenoid pathway, leading to lesions made up of parakeratotic cells, often linked to genetic mutations impacting cholesterol synthesis.
- A case study of a 56-year-old male with Mibelli porokeratosis showed that traditional treatments were ineffective for a persistent finger lesion that didn’t heal for two years.
- The introduction of a topical ointment containing 2% lovastatin and 2% cholesterol resulted in significant improvement after nine months, suggesting promising potential for this treatment approach in managing porokeratosis.
A Case of Disseminated Superficial Actinic Porokeratosis Successfully Treated With Topical Lovastatin/Cholesterol Gel.
Cureus
June 2023
Department of Dermatology, Las Vegas Dermatology, Las Vegas, USA.
Disseminated superficial actinic porokeratosis (DSAP) is a disorder of abnormal keratinization for which there is no standard treatment. Treatment modalities that have traditionally been utilized with varying success include ablative therapies, topical pharmacologic treatments, surgical excision, and retinoids. The underlying pathophysiology of DSAP is secondary to genetic mutations in the mevalonate biosynthesis pathway, and thus topical lovastatin/cholesterol presents a promising treatment modality for this condition.
View Article and Find Full Text PDFA rare case of punctate porokeratosis treated with topical lovastatin/cholesterol.
JAAD Case Rep
May 2023
Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis: A Randomized Clinical Trial.
JAMA Dermatol
May 2023
Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston.
Importance: Disseminated superficial actinic porokeratosis (DSAP) is an inherited or sporadic disorder of keratinization associated with germline variations. There is no effective standard of care therapy for DSAP, but treatment with topical lovastatin combined with cholesterol cream has shown promise.
Objectives: To evaluate and compare the safety and efficacy of topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol) and topical lovastatin 2% cream (lovastatin) alone in adults diagnosed with DSAP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!